- Home
- SPRO vs CRNT Comparison
SPRO vs CRNT Comparison
Compare SPRO & CRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- CRNT
- Stock Information
- Founded
- SPRO 2013
- CRNT 1996
- Country
- SPRO United States
- CRNT Israel
- Employees
- SPRO N/A
- CRNT N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- CRNT Radio And Television Broadcasting And Communications Equipment
- Sector
- SPRO Health Care
- CRNT Technology
- Exchange
- SPRO Nasdaq
- CRNT Nasdaq
- Market Cap
- SPRO 164.4M
- CRNT 186.7M
- IPO Year
- SPRO 2017
- CRNT 2000
- Fundamental
- Price
- SPRO $2.91
- CRNT $2.60
- Analyst Decision
- SPRO Buy
- CRNT Strong Buy
- Analyst Count
- SPRO 4
- CRNT 5
- Target Price
- SPRO $5.00
- CRNT $5.85
- AVG Volume (30 Days)
- SPRO 1.6M
- CRNT 712.3K
- Earning Date
- SPRO 08-04-2025
- CRNT 08-06-2025
- Dividend Yield
- SPRO N/A
- CRNT N/A
- EPS Growth
- SPRO N/A
- CRNT 367.84
- EPS
- SPRO N/A
- CRNT 0.25
- Revenue
- SPRO $44,584,000.00
- CRNT $394,344,000.00
- Revenue This Year
- SPRO N/A
- CRNT $3.12
- Revenue Next Year
- SPRO N/A
- CRNT $7.89
- P/E Ratio
- SPRO N/A
- CRNT $10.21
- Revenue Growth
- SPRO N/A
- CRNT 11.94
- 52 Week Low
- SPRO $0.51
- CRNT $1.95
- 52 Week High
- SPRO $3.09
- CRNT $5.73
- Technical
- Relative Strength Index (RSI)
- SPRO 71.62
- CRNT 64.67
- Support Level
- SPRO $2.79
- CRNT $2.40
- Resistance Level
- SPRO $3.03
- CRNT $2.49
- Average True Range (ATR)
- SPRO 0.12
- CRNT 0.09
- MACD
- SPRO -0.08
- CRNT 0.02
- Stochastic Oscillator
- SPRO 43.75
- CRNT 97.50
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and global distribution of its business, providing high-capacity wireless connectivity solutions to global markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the major revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.